Evidence map›Paper›PMID 28406525›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2017

An improved radiosynthesis of O-(2-[

Kiel D Neumann, Charles M Thompson, Joseph E Blecha, John M Gerdes, Henry F VanBrocklin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. [The Journal of pharmacology and experimental therapeutics · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Radiosynthesis of O-(1-[Journal of labelled compounds & radiopharmaceuticals · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kiel D NeumannDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.ORCID 0000-0001-9093-3522
Charles M ThompsonDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA.
Joseph E BlechaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
John M GerdesDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA.
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.

Funding

Molecular Imaging of Chemical Threats and CountermeasuresU01NS092495 · NINDS · UNIVERSITY OF MONTANA · PI GERDES, JOHN M, THOMPSON, CHARLES MARK · 2015 to 2019
$3.9M
NINDS NIH HHS U01 NS092495
6 · The paper itself

Abstract

O-(2-Fluoroethyl)-O-(p-nitrophenyl) methylphosphonate 1 is an organophosphate cholinesterase inhibitor that creates a phosphonyl-serine covalent adduct at the enzyme active site blocking cholinesterase activity in vivo. The corresponding radiolabeled O-(2-[

Indexed as

Positron-Emission TomographyChemistry Techniques, SyntheticCholinesterasesOrganophosphonatesRadioactive TracersCholinesterasesO-(2-fluoroethyl)-O-(p-nitrophenyl)methylphosphonateOrganophosphonatesRadioactive Tracers[18F]-fluoroethanolacetylcholinesterasebis-(p-nitrophenyl) methylphosphonatefluorine-18positron emission tomography (PET)β-fluoroethoxyphosphonate

Identifiers

PMID28406525
PMCPMC6031433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.